Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2019 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 849.66K | 851.49K | 763.46K | 696.36K | 0.00 | 0.00 |
Gross Profit | 50.19K | 287.44K | 91.85K | 121.65K | 0.00 | -1.12K |
EBITDA | -6.55M | -6.26M | -1.45M | -9.88M | -745.51K | -310.99K |
Net Income | -6.91M | -6.61M | -2.33M | -17.38M | -959.48K | -311.66K |
Balance Sheet | ||||||
Total Assets | 2.47M | 2.38M | 2.58M | 3.79M | 2.76M | 507.25K |
Cash, Cash Equivalents and Short-Term Investments | 15.58K | 256.58K | 187.56K | 1.03M | 264.06K | 271.16K |
Total Debt | 788.02K | 793.56K | 919.74K | 887.22K | 2.58M | 41.98K |
Total Liabilities | 2.63M | 2.56M | 2.27M | 1.71M | 2.77M | 18.41K |
Stockholders Equity | -164.33K | -172.97K | 314.72K | 2.07M | -8.88K | 488.85K |
Cash Flow | ||||||
Free Cash Flow | -1.37M | -804.21K | -1.18M | -2.38M | -1.67M | -409.37K |
Operating Cash Flow | -1.36M | -783.36K | -1.18M | -2.16M | -693.52K | -311.08K |
Investing Cash Flow | 173.91K | 162.67K | -4.10K | 2.19M | -1.02M | -98.29K |
Financing Cash Flow | 1.16M | 689.71K | 346.17K | 727.93K | 1.80M | 700.53K |
HYTN Innovations Inc. has received its first international purchase order for Good Manufacturing Practices (GMP) cannabis vape cartridges, marking a significant milestone in its collaboration with SNDL. This order, which involves 1000 one-gram live resin vape cartridges, is set to be exported to the United Kingdom, pending permit approvals, and underscores HYTN’s commitment to quality and its capability to serve regulated international markets. This development highlights the company’s growing influence in the global pharmaceutical cannabis market and its dedication to expanding its product portfolio with high-quality GMP cannabis products.
HYTN Innovations Inc. has received Good Manufacturing Practices (GMP) certificates from Health Canada for its manufacturing facility in Kelowna, confirming compliance for the United States, Bermuda, and Israel. These certifications enhance HYTN’s ability to support drug registrations, facilitate clinical trials, and offer contract manufacturing for cannabis and psilocybin-based pharmaceuticals, positioning the company for international growth and strengthening its leadership in high-quality manufacturing practices.